Agendia, Inc.: Data Presented at the Miami Breast Cancer Conference Show MammaPrint and BluePrint Accurately Predict Pathologic Complete Response Rate Regardless of Age
(1) Results support use of Agendias genomic tests to better tailor pre-operative treatment and timing for surgery Agendia, Inc., a world leader in precision oncology for breast cancer, announced new data from the prospective Neoadjuvant Breast Symphony Trial (NBRST) which demonstrate the predictive and prognostic abilities of MammaPrint and BluePrint , and underpin both assays pre-operative utility in pre-and post-menopausal patients. A poster highlighting these findings will be presented at t...
United States William Audeh James Pellicane Terri Clevenger Bon Secours Cancer Institute Agendia Inc
Source: finanznachrichten.de